Non-steroidal anti-inflammatory drugs in cancer treatment

Bibliography

• JAFFE BM: Prostaglandins and cancer: an update. Prostaglandins (1974) 6:453–461.
   PubMed Web of Science ®Google Scholar
• KARMALI RA: Prostaglandins and cancer. Prostaglandins (1980) 5:11–28.
   Google Scholar
• MARNETT LI: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. (1992) 52:5575–5589.
   PubMed Web of Science ®Google Scholar
• LEVY GN: Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs and colon cancer. FASEB J. (1997) 11:234–247.
   Google Scholar
• MARNETT LI: Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyradicals as positive intermediates. Environ. Health Perspec. (1990) 88:5–12.
   PubMedGoogle Scholar
• ERASHI M, NOGUCHI M, KINOSHITA K, TANAKA M: Effects of eiconanoid synthesis inhibitors on the in vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line. Oncology (1995) 52:150–155.
   Google Scholar
• LUPULESCU A: Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot. Essent. Fato Acids (1996) 54:83–94.
   Google Scholar
• KELLOFF GJ, HAWK ET, KARP JE et al: Progress in clinical chemoprevention. Semi]. Oncol (1997) 24:241–252.
   PubMedGoogle Scholar
• HONG WK, SPORN MB: Recent advances in chemoprevention of cancer. Science (1997) 278:1073–1077.
   PubMed Web of Science ®Google Scholar
• •A good review of cancer chemoprevention.
   Google Scholar
• XIE WL, ROBERTSON DL, SIMMONS DL: Mitogen-inducible prostaglandin G/H synthase: a target for nonsteroidal anti-inflammatory drugs. Drug Dev. Res. (1992) 25:245–265.
   Google Scholar
• SMITH WL, GARAVITO RM, DEWITT DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2.j Biol. Chem. (1996) 271:33157–33160.
   PubMed Web of Science ®Google Scholar
• SIMMONS D, XIE W, CHIPMAN JG, EVETT GE: Multiple cyclooxygenases: cloning of a mitogen-inducible form. In: Prostaglandin, Leukotrieries, Lipoxins and PAE Bailey J (Ed.), Plenum Press, New York (1991):67–78.
   Google Scholar
• O'NEILL GP, FORD-HUTCHINSON AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissue. FEBS Lett. (1993) 330:156–160.
   PubMed Web of Science ®Google Scholar
• DEWITT DL, SMITH WL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Nat] Acad. Sci. USA (1988) 85:1412–1416.
   PubMed Web of Science ®Google Scholar
• •First cloning of the entire coding region of COX-1.
   Google Scholar
• MERLIE JP, FAGAN D, MUDD J, NEEDLEMAN P: Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). I Biol. Chem. (1988) 283:3550–3555.
   Google Scholar
• FUNK C, FUNK L, KENNEDY ME, PONG AS, FIZGERALD CA: Human plateletierythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB (1991) 5:2304–2312.
   PubMed Web of Science ®Google Scholar
• JOUZEAU J-Y, TERLAIN B, ABID A, NEDELEC E, NETTER P: Cyclooxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs (1997) 53:563–582.
   Google Scholar
• O'BANION MK, WINN VD, YOUNG DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Li. USA (1992) 89:4888–4892.
   PubMed Web of Science ®Google Scholar
• SMITH WL, MEADE EA, DEWITT DL: Interactions of PGH synthase isoenzymes 1 and 2 with NSAIDs. Ann. NY Acad. Sci. (1994) 744:50–57.
   PubMed Web of Science ®Google Scholar
• TSUJII M, DUBOIS RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpression prostaglandin endoperoxide synthase-2. Cell (1995) 83:493–501.
   PubMed Web of Science ®Google Scholar
• SHENG H, SHAO J, MORROW JD, BEAUCHAMP RD, DUBOIS RN: Modulation of apoptosis and Bc1-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. (1998) 58:362–366.
   PubMed Web of Science ®Google Scholar
• KAWAMORI T, RAO CV, SEIBERT K, REDDY BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. (1998) 58:409–412.
   PubMed Web of Science ®Google Scholar
• PIAZZA GA, ALBERTS DS, HIXSON LJ et al.: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. (1997) 57:2909–2915.
   PubMed Web of Science ®Google Scholar
• WINDE G, LUGERING N, GLODNY B et al.: Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention. Cancer Lett. (1998) 134:201–207.
   Google Scholar
• SUNG J, RUSSELL RI, YEOMANS N etal.: Nonsteroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. Castroenterol. Hepato] (2000) 15:G58–68.
   Google Scholar
• HAWKEY C, LAINE L, SIMON T etal.: Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2000) 43:370–377.
   Google Scholar
• WEAVER AL: Rofecoxib: clinical pharmacology and clinical experience. Clin. Ther. (2001) 23:1323–1338.
   PubMed Web of Science ®Google Scholar
• OKAMOTO T, HINO O: Expression of cyclooxygenase-1 and -2 mRNA in rat tissues: tissue-specific difference in the expression of the basal level of mRNA. Ma] Med. (2000) 6:455–457.
   Google Scholar
• LI JJ, NORTON MB, REINHARD EJ etal.: Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally-active anti-inflammatory agents. I Med. Chem. (1996) 39:1846–1856.
   Google Scholar
• YAMAGUCHI T, HIROSE K, NAKAMURA Y, SUGENO K: The inhibitory activities of 480156-S and its related compounds on prostaglandin synthetase. Nippon Yakurigaku Zasshi (1987) 90:295–302.
   Google Scholar
• CALD WELL J, HUTT AJ, FOURNEL-GIGLEUX S: The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem. Pharmaco] (1988) 37:105–114.
   Google Scholar
• DUFFY CI ELLIOTT DJ, O'CONNOR RA et al.: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of nonsteroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer (1998) 34:1250–1259.
   Google Scholar
• PEGG A: Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. (1988) 48:759–774.
   PubMed Web of Science ®Google Scholar
• LI H, SCHUT HA, CONRAN P et al.: Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and protaglandin E2 levels in rat colon. Carciriogeriesis (1999) 20:425–430.
   PubMedGoogle Scholar
• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics, 2000. CA Cancer J. Clin. (2000) 50:7–33.
   PubMed Web of Science ®Google Scholar
• DEAN JL, BROOK M, CLARK AR, SAKLATVALA J: p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. I Biol. Chem. (1999) 274:264–269.
   Google Scholar
• SCHMEDTJE JF Jr, JI YS, LIU WL, DUBOIS RN and RUNGE MS: Hypoxia induces cyclooxygenase-2 via the NF- icB p65 transcription factor in human vascular endothelial cells. j Biol. Chem. (1997) 272:601–608.
   Google Scholar
• RIENDEAU D, CHARLESON S, CROMLISH W et al.: Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. I Physio] Pharmaco] (1997) 75:1088–1095.
   PubMed Web of Science ®Google Scholar
• HOLZER P, JOCIC M, CABRE MAULEON D: Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses. Inllarnm. Res. (2001) 50:602–608.
   PubMed Web of Science ®Google Scholar
• WECHTER W, MURRAY E, KANTOCI D et al.: Treatment and survival study in the C57BL/6J-APCmEn/+ Win) mouse with R-flurbiprofen. Life Sci. (2000) 66:745–753.
   Google Scholar
• WECHTER W, LEIPOLD D, MURRAY E et al.: E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the RAMP mouse. Cancer Res. (2000) 60:2203–2208.
   PubMed Web of Science ®Google Scholar
• RAZ A: Is inhibition of cyclooxygenase required for the antitumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem. Pharmaco] (2002) 63:343–347.
   PubMed Web of Science ®Google Scholar
• ELDER DJ, HALTON DE, HAGUE A, PARASKEVA C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. (1997) 3:1679–1683.
   PubMed Web of Science ®Google Scholar
• ZHANG X, MORHAM SG, LANGENBACH R, YOUNG D: Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. Exp. Med. (1999) 190:451–459.
   PubMed Web of Science ®Google Scholar
• DEVITA VT: The consequences of the chemotherapy of Hodgkin's disease: The 10th Annual David A. Karnofsky Lecture. Cancer (1981) 47:1–13.
   Google Scholar
• OSHIMA M, MURAI(HATA) N, KARGMANN S et al.: Chemoprevention of intestinal polyposis in the Apc°716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. (2001) 61:17733–17740.
   Google Scholar
• SMIGEL K: Arthritis drug approved for polyp prevention blazes trail for other prevention trials. j Natl. Cancer Inst. (2000) 92:297–299.
   Google Scholar
• STEINBACH G, LYNCH E PHILLIPS R et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. j Med. (2000) 342:1946–1952.
   PubMed Web of Science ®Google Scholar
• WULLEN B, MUHLHOFER A, ZOLLERW: Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis. Z Castroenterol. (2001) 39:335–337.
   Google Scholar
• SIMON L, WEAVER A, GRAHAM D et al: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 282:1921–1928.
   PubMed Web of Science ®Google Scholar